Nature Communications: PD-1/CD137 dual antibody has excellent effect and good safety

Immune checkpoint therapy represented by PD-1/PD-L1 has significantly changed the treatment prospects of some cancers, but it is not enough for many cancer patients

Several anti-CD137 agonistic antibodies have given people new hope, but their hepatotoxicity is so strong that they cannot be used clinically

Recently, Cinda Bio's research team published a research paper titled Cancer immune therapy with PD-1-dependent CD137 co-stimulation provides localized tumour killing without systemic toxicity in Nature Communications

The study reported that a CD137/PD-1 bispecific antibody, IBI319, can be preferentially enriched in tumor-infiltrating T cells and NK cells with high PD-1 expression.

IBI319 is designed as a fully humanized IgG1 molecule and contains a bivalent Fab fragment that binds to PD-1 and CD137, respectively

Next, the research team tried to explore the in vivo efficacy and safety of IBI319

Finally, the research team determined the pharmacokinetics and safety characteristics of IBI319 through cynomolgus monkeys

In addition, in all dose groups, the PD-1 occupancy rate reached saturation 5 minutes after administration, and showed a correlation between binding durability and drug concentration

In summary, the study evaluated the PD-1/CD137 bispecific antibody IBI319, which can be preferentially enriched in tumor-infiltrating T cells and NK cells with high PD-1 expression.

It is reported that the phase 1 clinical trial of IBI319 has been led by Professor Wu Yilong, the life director of Guangdong Provincial People's Hospital and the honorary director of Guangdong Lung Cancer Research Institute

Original source:

Qiao, Y.